๐ Ionis $IONS crashes 21% premarket as Wainua heart drug flunks Phase 3
Ionis Pharmaceuticals and partner AstraZeneca ($AZN, -8%) revealed Thursday morning that the CARDIO-TTRansform Phase 3 trial of eplontersen (Wainua) in ATTR-CM patients missed its primary endpoint โ reducing cardiovascular mortality and recurrent heart events vs. placebo over 140 weeks. The failure removes a key pipeline asset for Ionis in the hotly contested TTR amyloidosis space. Full data is slated for the ESC Congress in August. Not financial advice. Does this open the door for rivals to dominate ATTR treatment, or is there still a path forward for Ionis?
โก 56 buzzing
562 views
๐ 0 subscribed